Todd Garland - NanoString Technologies Chief Officer
| NSTGDelisted Stock | USD 4.11 0.22 5.08% |
Executive
Todd Garland is Chief Officer of NanoString Technologies
| Age | 54 |
| Phone | 206 378 6266 |
| Web | https://www.nanostring.com |
NanoString Technologies Management Efficiency
The company has return on total asset (ROA) of (0.3087) % which means that it has lost $0.3087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2856) %, meaning that it created substantial loss on money invested by shareholders. NanoString Technologies' management efficiency ratios could be used to measure how well NanoString Technologies manages its routine affairs as well as how well it operates its assets and liabilities.NanoString Technologies currently holds 250.5 M in liabilities with Debt to Equity (D/E) ratio of 2.22, implying the company greatly relies on financing operations through barrowing. NanoString Technologies has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NanoString Technologies' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Florian Baumgartner | 10X Genomics | N/A | |
| Jim Goodrich | 10X Genomics | N/A | |
| David Ege | Seres Therapeutics | 50 | |
| Robert Brainin | Veracyte | 53 | |
| Sara Pellegrino | Iovance Biotherapeutics | N/A | |
| Phillip MD | Veracyte | 58 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Alexander Wong | 10X Genomics | N/A | |
| Mennah Moustafa | 10X Genomics | N/A | |
| JD Esq | Syros Pharmaceuticals | 56 | |
| Keith Gligorich | Veracyte | N/A | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| James Wilbur | 10X Genomics | 58 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Eric Olson | Syros Pharmaceuticals | 66 | |
| Brian MBA | Iovance Biotherapeutics | N/A | |
| Steven French | Veracyte | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| James MBA | Iovance Biotherapeutics | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Matthew Henn | Seres Therapeutics | 49 | |
Management Performance
| Return On Equity | -10.29 | |||
| Return On Asset | -0.31 |
NanoString Technologies Leadership Team
Elected by the shareholders, the NanoString Technologies' board of directors comprises two types of representatives: NanoString Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NanoString. The board's role is to monitor NanoString Technologies' management team and ensure that shareholders' interests are well served. NanoString Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NanoString Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Garland, Chief Officer | ||
| Joseph Beechem, Chief Development | ||
| Mark Winham, Senior Operations | ||
| Chad Brown, Senior Vice President - Sales and Marketing | ||
| Thomas MBA, Chief Officer | ||
| Elizabeth Schneider, Senior Manager | ||
| Kathryn SuraceSmith, Senior Secretary | ||
| Praveer Sharma, Field Scientist | ||
| Bradley Gray, CEO and President and Director | ||
| David Ghesquiere, Senior Vice President - Corporate & Business Development | ||
| Anne Valk, Executive | ||
| Mary Allen, Vice President - Operations | ||
| Douglas Farrell, Vice Communications | ||
| Philippa Webster, Senior Scientist |
NanoString Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NanoString Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.29 | |||
| Return On Asset | -0.31 | |||
| Profit Margin | (1.02) % | |||
| Operating Margin | (0.76) % | |||
| Current Valuation | 153.97 M | |||
| Shares Outstanding | 48.12 M | |||
| Shares Owned By Insiders | 3.16 % | |||
| Shares Owned By Institutions | 96.84 % | |||
| Number Of Shares Shorted | 6.04 M | |||
| Price To Earning | (4.62) X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in NanoString Stock
If you are still planning to invest in NanoString Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NanoString Technologies' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |